Skystar Bio-Pharmaceutical Company
Skystar Bio-Pharmaceutical — Investor Presentation (October 2009)
30 slides from Skystar Bio-Pharmaceutical's investor presentation, Oct 14, 2009

Slide 1: Skystar Bio-Pharmaceutical Co., Ltd.
bard SKYSTAR pad Bio-PHARMACEUTICAL CO.,LTD. SKYSTAR Weibing Lu, Chairman and CEO R. Scott Cramer, Director

Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation may be "forward-looking statements” within the meaning of federal securities laws. The matters discussed herein that are forward-looking statements are based on current management expectations that involve risks and uncertainties that may result

Slide 3: Company Overview
Company Overview Leading China-based producer and distributor of veterinary medicines, vaccines, microorganisms and feed additives » GMP production facilities and processes » Headquartered in Xi’an, Shaanxi Province, China = 216 employees «= Only U.S. listed veterinary supply company in China

Slide 4: 2009 Recent Events
2009 Recent Events

Slide 5: Skystar Snapshot
Skystar Snapshot a Stock Price (Oct. 8, 2009) $15.90 52 Week Range $ 1.25 - $22.49 Shares Outstanding 3.5M Market Cap $55.33 P/E (TTM — Adjusted)* 4.96 1HO9 Revenues $10.1M 1HO9 Net Income / Adjusted Net Income* $0.50 / $1.28 ~ Adjusted net income excludes a net $1.44 million loss in 1H09 for the ch

Slide 6: Why Invest in Skystar
Why Invest in Skystar v Leader in young, fragmented industry: demand exceeds supply Compelling market opportunity Extensive product lines covering all key segments of the animal ‘arming industry Large, established sales and distribution network Diverse customer base covers all 29 farm producing prov

Slide 7: Growing Industry
Growing Industry Consolidation of family owned/operated farms and improved technology are driving demand and growth in the veterinary industry > China is the world’s largest producer of poultry and livestock >» Government supports rapid development of modernization > GMP certification required by PR

Slide 8: Products Lines Address Major Industry Segments
Products Lines Address Major Industry Segments Year ended 12/31/08 asa Percentage of Total Veterinary Medications $17,535,757 68%| $ 7,146,031 56% Micro-organism $ 5,868,623 23% | $ 4,087,025 32% Feed Additives $ 1,189,108 5%| $§ 663,455 5% Veterinary Vaccines $ 990,958 4%| $ 879,039 T% Total $25,58

Slide 9: Veterinary Medications
Veterinary Medications Year ended 12/31/08 Veterinary Medications $17,535,757 as a Percentage of Total 68% | $ 7,146,031 Total $25,584,446 100% | $12,775,550 140 products » 34 drugs approved in 2008 > Target: 40 drug approvals in 2009 » Focus on higher margin products SkysTar WES 0 Pranmsceumcal co,

Slide 10: Micro-organism
Micro-organism r Year ended 12/31/08 as a Percentage of Total Micro-organism $ 5,868,623 23% | $ 4,087,025 32% Total $25,584,446 100% | $12,775,550 100% 13 products » In house production of microbial strain significantly reduced production costs in 2008 » Constructing new production facility project

Slide 11: Feed Additives
Feed Additives Year ended 12/31/08 Feed Additives $ 1,189,108 $ 663,455 Total $25,584,446 $12,775,550 10 products » Increase yield > Improve health of livestock

Slide 12: Veterinary Vaccines
Veterinary Vaccines 1 Year ended 12/34/08 as a Percentage of Total Veterinary Vaccines $ 990,958 4% | $ 879,039 % Total $25,584,446 100% | $12,775,550 100% 10 products (active and inactive) » Constructing new production facility projected to increase production capacity by 2,300% >» Initiate product

Slide 13: Effective R&D Capabilities
Effective R&D Capabilties Xi’an R&D Facilities Shanghai R&D Facilities Over 25 researchers responsible for developing new medicines and 5 researchers from the Chinese vaccines in response to epidemics, Academy of Agricultural Sciences pandemics and diseases Two Lab: Responsible for evaluating and zi

Slide 14: Bringing Products to Market
Bringing Products to Market Launched several products targeting porcine reproductive and respiratory syndrome (PRRS), aka Blue Ear Disease » April, 2007: launched Chinese Goldthread (Huanglian) Detoxification Powder ("CGDP") » July, 2007: launched First Aid Kit for Swine High Fever Syndrome » Cures

Slide 15: Customers and Distribution
Customers and Distribution 5

Slide 16: Skystar's Competitive Advantages
Skystar’s Competitive Advantages Only U.S. listed veterinary supply company in China Largest competitors are state-owned enterprises Established over 350 franchise stores in 2007-2008 Distribution network covering 29 provinces in China Majority of competitors only offer 1-2 product lines High barrie

Slide 17: Growth Strategy
Growth Strategy + 40 new product introductions planned for 2009 In igere| uce New * Covers all four product lines + Leverage R&D capabilities to continue to add to portfolio P rod U cts and increase market share Expa n d * Two new facilities scheduled for completion in late 4Q09 Man ufactu ring + Bu

Slide 18: Annual Revenue Growth
Annual Revenue Growth $30.00 $25.00 $20.00 $15.00 $10.00 $5.00 $0.00 $25.58 Revenue (SMM) $9.80 $6.00 $4.00 mE = 2003 2004 2005 2007 $15.10 it 2008 18

Slide 19: 1H Revenue
1H Revenue $14.00 $12.00 $10.07 $10.00 $8.00 $7.16 $8.00 $4.74 $4.00 $2.00 $0.00 HOT 1HO8 1HO9 laid Bio. PHARMACEUTICAL CO.LTD. 19

Slide 20: Annual Gross Margin Expansion
Annual Gross Margin Expansion $14.00 $12.00 $10.00 $8.00 $6.00 $4.00 $2.00 $0.00 latad Bio. PHARMACEUTICAL CO.,LTD, o $12.78 7 60.0% 4% 7% 250.0% are 4.7% $8.34 40.0% 30.0% $4.40 00% $3.00 $1.80 10.0% $0.60 [ ] = : , , f aa% 2003 2004 2005 2006 2007 2008 lam Gross Margin (SMM) —- Gross Margin (%) 20

Slide 21: 1H Gross Margin Expansion
1H Gross Margin Expansion $6.00 + $3.00 $2.63 $3.70 51.3% $5.16 (HOT | Gross Margin (SMM) 4HOB -* Gross Margin (%) 1HO9 a 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% 21

Slide 22: High Margin Products
High Margin Products 12 Months Ended 12/31/08 Revenues Gross Margin Veterinary Medications $17,535,757 | $7,146,031 Micro-organism 5,868,623 4,087,025 Feed Additives 1,189,108 663,455 Vaccines 990,958 879,039 Total $25,584,446 $12,775,550

Slide 23: Annual Adjusted Net Income Growth
Annual Adjusted Net Income Growth 7.00 + $6.70 — 30.0% 6.2% 6.00. | 25.0% 5.00 + + 20.0% 4.00 + | 15.0% 3.00 + + 10.0% 2.00 + 1.00 + | 5.0% 0.00 0.0% 2003 2004 2005 2006 2007 2008 EE Net Income ($MM) ~~ —@— Profit Margin

Slide 24: 1H Adjusted Net Income
1H Adjusted Net Income $4.00 $3.50 $3.00 $2.50 $2.00 $1.50 $1.00 $0.50 $0.00 23.7% $2.39 1HO7 1HO8 1HO9 (mNet Income ($MM) —¢-Profit Margin 24.5% 23.5% 22.5% 21.5% 20.5% 19.5% 18.5% 24

Slide 25: Select Balance Sheet Data
Select Balance Sheet Data As of June 30, 2009 Cash and Restricted Cash $411,000 Current Assets $17.6M Current Liabilities $6.36M On July 7, 2009, Skystar completed an equity offering for gross proceeds of ~21.0M Skustar WEN Bo Prarnmaceumcal co.L7o.

Slide 26: Weibing Lu - Chairman and CEO
Weibing Lu - Chairman and CEO =» Founded Xian Tianxing Bio- Pharmaceutical Co., Ltd. (our operating company in China) in 1997 « BS from Wuhan University in 1985 and MBA from Xi'an Jiaotong University in 1999 « Awarded Outstanding Entrepreneur of Xi'an Feed Industry in 2002 « Appointed as a Director

Slide 27: Wei Wen - Director and Vice General Manager
Wei Wen - Director and Vice General Manager « Secretary of the Board and Vice GM since founding of the Company « Graduated from Xi’an University of Science and Industry in 1986 « Manager and Vice GM at the Sales Department of two companies before joining Skystar FA Sxustar $e Bo PHaRmAceurAL co.L-To

Slide 28: Bennet P. Tchaikovsky, CPA, Esq. - CFO
Bennet P. Tchaikovsky, CPA, Esq. - CFO « Part-time CFO of China Jo-Jo Drugstores, Inc. (OTCBB: CJJD.OB) « Former CFO of Innovative Card Technologies, Inc. (OTCBB: INVC) E Director of Ever-Glory International Group (NYSE AMEX: EVk) « Director of Sino Clean Energy Inc. (OTCBB: SCLX.OB) « Graduate of S

Slide 29: Erna Gao - VP Finance & Administration
Erna Gao - VP Finance & Administration « Served as our Chief Financial Officer from March 2004 through May 2008 « Former Chief Accountant at Dongda Petroleum Company « Graduated from Xi'an TB University with a degree in Accounting 29

Slide 30: Scott Cramer, Director & US Spokesperson
Scott Cramer, Director & US Spokesperson » Former CEO, CFO of The Cyber Group » Founder and President of Cramer & Associates, a firm specializing in rh} retirement management, estate planning and investments » Registered Representative - Series 7, 63, 65 30
Source: SEC EDGAR · 8-K filed Oct 14, 2009
More decks from Skystar Bio-Pharmaceutical Company
RENN Investor Conference, May 14, 201037 slides · May 17, 2010
Investor Presentation (March 2010)41 slides · Mar 17, 2010
Investor Presentation (March 2010)34 slides · Mar 8, 2010
Investor Presentation (November 2009)40 slides · Nov 20, 2009
Investor Presentation (September 2009)43 slides · Sep 9, 2009
Investor Presentation (July 2009)24 slides · Jul 31, 2009